{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:15:07Z","timestamp":1784330107009,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.thromres.2011.03.003","type":"journal-article","created":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T16:56:55Z","timestamp":1307552215000},"page":"274-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Urokinase plasminogen activator receptor levels in Behcet's disease"],"prefix":"10.1016","volume":"128","author":[{"given":"Serhat","family":"Birengel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Nil\u00fcfer","family":"Yal\u00e7\u0131nda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Yal\u00e7\u0131nda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Sahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Figen","family":"Bat\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2011.03.003_bb0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0049-3848(02)00006-3","article-title":"Pathological haemostasis and \u2018prothrombotic state\u2019 in Beh\u00e7et's disease","volume":"105","author":"Kiraz","year":"2002","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.thromres.2011.03.003_bb0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/archdermatol.2008.570","article-title":"Antiphosphatidylserine-prothrombin complex antibodies in 3 patients with Beh\u00e7et disease involving superficial vein thrombophlebitis","volume":"145","author":"Kawakami","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.thromres.2011.03.003_bb0015","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000040847","article-title":"Haemostasis, thrombosis, and endothelium in Beh\u00e7et's disease","volume":"99","author":"Haznedaro\u011flu","year":"1998","journal-title":"Acta Haematol"},{"key":"10.1016\/j.thromres.2011.03.003_bb0020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/blood.V94.1.172.413k17_172_178","article-title":"Contribution of distinct adhesive interactions to platelet aggregation in flowing blood","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2011.03.003_bb0025","series-title":"Hemostasis and thrombosis: basic principles and clinical practice","first-page":"3","article-title":"Overview of hemostasis","author":"Colman","year":"2001"},{"key":"10.1016\/j.thromres.2011.03.003_bb0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1055\/s-2000-13216","article-title":"Fibrin clot formation and lysis: basic mechanisms","volume":"26","author":"Sidelmann","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.thromres.2011.03.003_bb0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1432-1327.1998.2520185.x","article-title":"The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule","volume":"252","author":"Dear","year":"1998","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.thromres.2011.03.003_bb0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0167-5699(97)01121-3","article-title":"uPA, uPAR, PAI- 1: Key intersection of proteolytic, adhesive and chemotactic highways?","volume":"18","author":"Blasi","year":"1997","journal-title":"Immunol Today"},{"issue":"5","key":"10.1016\/j.thromres.2011.03.003_bb0045","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1517\/13543781003767400","article-title":"Modulators of the urokinase-type plasminogen activation system for cancer","volume":"19","author":"Hildenbrand","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.thromres.2011.03.003_bb0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ctrv.2007.10.005","article-title":"Evolving role of uPA\/uPAR system in human cancers","volume":"34","author":"Dass","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.thromres.2011.03.003_bb0055","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/sj.leu.2403250","article-title":"CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders:a review","volume":"18","author":"Bene","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2011.03.003_bb0060","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1111\/j.1572-0241.1998.00718.x","article-title":"Arterial thrombosis leading to intestinal infarction in a patient with Beh\u00e7et's disease associated with protein C deficiency","volume":"93","author":"Bayraktar","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.thromres.2011.03.003_bb0065","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1055\/s-0038-1648428","article-title":"Extensive venous thrombosis in a case of Beh\u00e7et's disease associated with heterozygous protein C deficiency (letter)Thromb","volume":"67","author":"Shehto","year":"1992","journal-title":"Haemostasis"},{"key":"10.1016\/j.thromres.2011.03.003_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1648128","article-title":"Beh\u00e7et syndrome associated with protein S deficiency","volume":"67","author":"Chafa","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.03.003_bb0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0049-3848(97)00063-7","article-title":"Protein S deficiency and antibodies to protein S in patients with Behc\u00b8et's disease","volume":"86","author":"Guermazi","year":"1997","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.thromres.2011.03.003_bb0080","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.2004.05072.x","article-title":"Activated protein C levels in Beh\u00e7et's disease and risk of venous thrombosis","volume":"126","author":"Navarro","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2011.03.003_bb0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0609.1996.tb00499.x","article-title":"Haemostatic markers of procoagulant inbalance in Beh\u00e7et's disease","volume":"57","author":"Haznedaroglu","year":"1996","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.thromres.2011.03.003_bb0090","first-page":"2404","article-title":"Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behc\u00b8et's disease","volume":"26","author":"Mader","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.thromres.2011.03.003_bb0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/030006059802600405","article-title":"Antithrombin III, protein C and protein S plasma levels in patients with Beh\u00e7et's disease","volume":"26","author":"Nal\u00e7aci","year":"1998","journal-title":"J Intern Med Res"},{"key":"10.1016\/j.thromres.2011.03.003_bb0100","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s002680010282","article-title":"Comparison of coagulation parameters for healthy subjects and Beh\u00e7et disease patients with and without vascular involvement","volume":"24","author":"Sengul","year":"2000","journal-title":"World J Surg"},{"key":"10.1016\/j.thromres.2011.03.003_bb0105","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/35.11.1178","article-title":"Coagulation factor V gene mutation increases the risk of venous thrombosis in Beh\u00e7et's disease","volume":"35","author":"G\u00fcl","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.thromres.2011.03.003_bb0110","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/ard.54.10.860","article-title":"Activated protein C resistance caused by factor V Arg506Gln mutation has no role in thrombotic manifestations of Beh\u00e7et's disease","volume":"54","author":"Lesprit","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.thromres.2011.03.003_bb0115","first-page":"2849","article-title":"Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombosis in Beh\u00e7et's disease","volume":"27","author":"Toydemir","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.thromres.2011.03.003_bb0120","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s002960050043","article-title":"Activated protein C resistance in Beh\u00e7et's disease","volume":"17","author":"Ko\u015far","year":"1998","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.thromres.2011.03.003_bb0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1034\/j.1600-0420.2003.00068.x","article-title":"Factor V Leiden and prothrombin gene G20210A mutations in ocular Beh\u00e7et disease","volume":"81","author":"Batio\u011flu","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.thromres.2011.03.003_bb0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00001721-200302000-00001","article-title":"Factor V Leiden mutation and PAI-1 gene 4G\/5G genotype in thrombotic patients with Behcet's disease","volume":"14","author":"Gurgey","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.thromres.2011.03.003_bb0135","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/rheumatology\/38.12.1298","article-title":"Procoagulant mutations and venous thrombosis in Beh\u00e7et's disease","volume":"38","author":"G\u00fcl","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2011.03.003_bb0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/art.20237","article-title":"Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet.s disease and deep vein thrombosis","volume":"51","author":"Silingardi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.thromres.2011.03.003_bb0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0049-3848(02)00085-3","article-title":"Coagulation parameters and plasma total homocysteine levels in Behcet's disease","volume":"106","author":"Lee","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2011.03.003_bb0150","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/407972","article-title":"Homocystein may involve in the pathogenesis of Beh\u00e7et's disease by inducing inflammation","author":"Kartal Durmazlar","year":"2008","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.thromres.2011.03.003_bb0155","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/ard.2003.014241","article-title":"Thrombophilic factors are not the leading cause of thrombosis in Beh\u00e7et's disease","volume":"63","author":"Leiba","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.thromres.2011.03.003_bb0160","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2133.1993.tb00172.x","article-title":"Anticardiolipin antibodies in Adamantiades \u2013Beh\u00e7et's disease","volume":"128","author":"Zouboulis","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.thromres.2011.03.003_bb0165","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/ard.43.5.746","article-title":"Anticardiolipin antibodies occurrence in Beh\u00e7et's syndrome","volume":"43","author":"Hull","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.thromres.2011.03.003_bb0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/BOR.0b013e32831de4e7","article-title":"Thromboembolic disease in vasculitis","volume":"21","author":"Tomasson","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.thromres.2011.03.003_bb0175","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1365-2141.2008.07078.x","article-title":"Fibrinolytic inhibitor levels and polymorphism in Beh\u00e7et disease and their association with thrombosis","volume":"141","author":"Ricart","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.thromres.2011.03.003_bb0180","first-page":"267","article-title":"Plasma thrombin activatable fibrinolysis inhibitor levels in Beh\u00e7et's disease","volume":"37","author":"Ozcan","year":"2007","journal-title":"Turk J Med Sci"},{"issue":"4","key":"10.1016\/j.thromres.2011.03.003_bb0185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.thromres.2004.09.010","article-title":"Thrombin activatable fibrinolysis inhibitor in Beh\u00e7et's disease","volume":"115","author":"Donmez","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2011.03.003_bb0190","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1055\/s-0038-1646409","article-title":"Coagulation and fibrinolytic activity in Beh\u00e7et's disease","volume":"66","author":"Hampton","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2011.03.003_bb0195","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archopht.1985.01050070061030","article-title":"Plasminogen activator activity levels in patients with Beh\u00e7et's syndrome","volume":"103","author":"Mishima","year":"1985","journal-title":"Arch Ophthalmol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384811001150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384811001150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:36:34Z","timestamp":1758735394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384811001150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0049384811001150"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2011.03.003","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urokinase plasminogen activator receptor levels in Behcet's disease","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2011.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}